Compare HHS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HHS | QNCX |
|---|---|---|
| Founded | 1923 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 17.5M |
| IPO Year | 1994 | 2019 |
| Metric | HHS | QNCX |
|---|---|---|
| Price | $4.60 | $31.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 104.0K | 15.4K |
| Earning Date | 05-14-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,570,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.00 | $0.08 |
| 52 Week High | $4.67 | $35.41 |
| Indicator | HHS | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 73.86 | 53.67 |
| Support Level | $4.14 | $29.95 |
| Resistance Level | N/A | $35.38 |
| Average True Range (ATR) | 0.10 | 2.10 |
| MACD | -0.03 | -0.16 |
| Stochastic Oscillator | 95.62 | 65.49 |
Harte-Hanks Inc is a customer experience company. The company operates three business segments: Revenue Solutions; Customer Care; and Fulfillment & Logistics Services. It derives maximum revenue from Fulfillment & Logistics Services segment. The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, monitoring and tracking, to support traditional and specialized mailings. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.